Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions

JACC: Heart Failure

Volumn 5, Issue 3, 2017, Pages 194-203

  Bhatt, Ankeet S ^a   DeVore, Adam D ^a,b   Hernandez, Adrian F ^a,b   Mentz, Robert J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

heart failure; influenza; pneumococcal; vaccination

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PNEUMOCOCCUS VACCINE;

ACUTE CORONARY SYNDROME; ANTIBODY PRODUCTION; AORTA ATHEROSCLEROSIS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART FAILURE; HEART PROTECTION; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; LEUKOCYTE MIGRATION; MOLECULAR MIMICRY; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIA; VACCINATION; COST BENEFIT ANALYSIS; DISEASE EXACERBATION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RISK FACTOR;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 85011278275     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.12.007     Document Type: Review

References (60)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
2. 2 Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
3. 3 Braunwald, E., Heart failure. J Am Coll Cardiol HF 1 (2013), 1–20.
4. 4 Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126 (2012), 65–75.
5. 5 Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
6. 6 Ajani, U.A., Ford, E.S., Mokdad, A.H., Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States. Am Heart J 149 (2005), 254–259.
7. 7 Chang, T.Y., Chao, T.F., Liu, C.J., et al. The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Heart Rhythm 13 (2016), 1189–1194.
8. 8 Alon, D., Stein, G.Y., Korenfeld, R., Fuchs, S., Predictors and outcomes of infection-related hospital admissions of heart failure patients. PloS One, 8, 2013, e72476.
9. 9 Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 168 (2008), 847–854.
10. 10 Centers for Disease Control and Prevention (CDC). Estimated Influenza Illnesses and Hospitalizations Averted by Vaccination—United States, 2014–15 Influenza Season. 2015. Available at: https://www.cdc.gov/flu/about/disease/2014-15.htm. Accessed July 10, 2016.
11. 11 McElhaney, J.E., Herre, J.M., Lawson, M.L., Cole, S.K., Burke, B.L., Hooton, J.W., Effect of congestive heart failure on humoral and ex vivo cellular immune responses to influenza vaccination in older adults. Vaccine 22 (2004), 681–688.
12. 12 Vu, T., Farish, S., Jenkins, M., Kelly, H., A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20 (2002), 1831–1836.
13. 13 Hamborsky, J., Kroger, A., Wolfe, C., (eds.) Epidemiology and Prevention of Vaccine-Preventable Diseases, 13 edition., 2015, Centers for Disease Control and Prevention, Atlanta, GA.
14. 14 Metersky, M.L., Masterton, R.G., Lode, H., File, T.M. Jr., Babinchak, T., Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 16 (2012), e321–e331.
15. 15 Shahangian, A., Chow, E.K., Tian, X., et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119 (2009), 1910–1920.
16. 16 Tomczyk, S., Bennett, N.M., Stoecker, C., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63 (2014), 822–825.
17. 17 Kobayashi, M., Bennett, N.M., Gierke, R., et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 64 (2015), 944–947.
18. 18 Harper, S.A., Fukuda, K., Uyeki, T.M., Cox, N.J., Bridges, C.B., Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 53 (2004), 1–40.
19. 19 Smith, S.C. Jr., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 58 (2011), 2432–2446.
20. 20 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
21. 21 Lindenfeld, J., Albert, N.M., Boehmer, J.P., et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 16 (2010), e1–e194.
22. 22 Perk, J., De Backer, G., Gohlke, H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 223 (2012), 1–68.
23. 23 Libby, P., Theroux, P., Pathophysiology of coronary artery disease. Circulation 111 (2005), 3481–3488.
24. 24 Berliner, J.A., Subbanagounder, G., Leitinger, N., Watson, A.D., Vora, D., Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 11 (2001), 142–147.
25. 25 Danesh, J., Collins, R., Appleby, P., Peto, R., Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 (1998), 1477–1482.
26. 26 Mendall, M.A., Patel, P., Asante, M., et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (British Cardiac Society) 78 (1997), 273–277.
27. 27 Kumar, A., Thota, V., Dee, L., Olson, J., Uretz, E., Parrillo, J.E., Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183 (1996), 949–958.
28. 28 Mann, D.L., Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002), 988–998.
29. 29 Levine, B., Kalman, J., Mayer, L., Fillit, H.M., Packer, M., Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990), 236–241.
30. 30 Oral, H., Dorn, G.W., Mann, D.L., Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem 272 (1997), 4836–4842.
31. 31 Gulick, T., Chung, M.K., Pieper, S.J., Lange, L.G., Schreiner, G.F., Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 86 (1989), 6753–6757.
32. 32 Balligand, J.L., Ungureanu, D., Kelly, R.A., et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 91 (1993), 2314–2319.
33. 33 Van Lenten, B.J., Wagner, A.C., Nayak, D.P., Hama, S., Navab, M., Fogelman, A.M., High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 103 (2001), 2283–2288.
34. 34 Carty, C.L., Heagerty, P., Nakayama, K., et al. Inflammatory response after influenza vaccination in men with and without carotid artery disease. Arterioscler Thromb Vasc Biol 26 (2006), 2738–2744.
35. 35 Posthouwer, D., Voorbij, H.A., Grobbee, D.E., Numans, M.E., van der Bom, J.G., Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine 23 (2004), 362–365.
36. 36 Binder, C.J., Horkko, S., Dewan, A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 (2003), 736–743.
37. 37 Caligiuri, G., Khallou-Laschet, J., Vandaele, M., et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50 (2007), 540–546.
38. 38 Hebert, K., Marzouka, G., Arcement, L., et al. Prevalence of vaccination rates in systolic heart failure: a prospective study of 549 patients by age, race, ethnicity, and sex in a heart failure disease management program. Congest Heart Fail 16 (2010), 278–283.
39. 39 Vardeny, O., Claggett, B., Udell, J.A., et al. Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial. J Am Coll Cardiol HF 4 (2016), 152–158.
40. 40 Gurfinkel, E.P., Leon de la Fuente, R., Mendiz, O., Mautner, B., Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 25 (2004), 25–31.
41. 41 Ciszewski, A., Bilinska, Z.T., Brydak, L.B., et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 29 (2008), 1350–1358.
42. 42 Phrommintikul, A., Kuanprasert, S., Wongcharoen, W., Kanjanavanit, R., Chaiwarith, R., Sukonthasarn, A., Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 32 (2011), 1730–1735.
43. 43 Udell, J.A., Zawi, R., Bhatt, D.L., et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 310 (2013), 1711–1720.
44. 44 Nichol, K.L., Nordin, J., Mullooly, J., Lask, R., Fillbrandt, K., Iwane, M., Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348 (2003), 1322–1332.
45. 45 Davis, J.W., Lee, E., Taira, D.A., Chung, R.S., Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan. Med Care 39 (2001), 1273–1280.
46. 46 Nichol, K.L., Margolis, K.L., Wuorenma, J., Von Sternberg, T., The Efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (1994), 778–784.
47. 47 Kopel, E., Klempfner, R., Goldenberg, I., Influenza vaccine and survival in acute heart failure. Eur J Heart Fail 16 (2014), 264–270.
48. 48 Mohseni, H., Kiran, A., Khorshidi, R., Rahimi, K., Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. Eur Heart J, 2016 Sep 22 [E-pub ahead of print].
49. 49 Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. MMWR Recomm Rep 62 (2013), 1–43.
50. 50 DiazGranados, C.A., Dunning, A.J., Kimmel, M., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 371 (2014), 635–645.
51. 51 Vardeny, O., Sweitzer, N.K., Detry, M.A., Moran, J.M., Johnson, M.R., Hayney, M.S., Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail 15 (2009), 368–373.
52. 52 Van Ermen, A., Hermanson, M.P., Moran, J.M., Sweitzer, N.K., Johnson, M.R., Vardeny, O., Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail 15 (2013), 560–564.
53. 53 Musher, D.M., Rueda, A.M., Kaka, A.S., Mapara, S.M., The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 45 (2007), 158–165.
54. 54 Ren, S., Newby, D., Li, S.C., et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis. Open Heart, 2, 2015, e000247.
55. 55 Lamontagne, F., Garant, M.P., Carvalho, J.C., Lanthier, L., Smieja, M., Pilon, D., Pneumococcal vaccination and risk of myocardial infarction. CMAJ 179 (2008), 773–777.
56. 56 Tseng, H.F., Slezak, J.M., Quinn, V.P., Sy, L.S., Van den Eeden, S.K., Jacobsen, S.J., Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA 303 (2010), 1699–1706.
57. 57 Fedson, D.S., Houck, P., Bratzler, D., Hospital-based influenza and pneumococcal vaccination: Sutton's Law applied to prevention. Infect Control Hosp Epidemiol 21 (2000), 692–699.
58. 58 Kale, M.S., Federman, A.D., Ross, J.S., Visits for primary care services to primary care and specialty care physicians, 1999 and 2007. Arch Intern Med 172 (2012), 1421–1423.
59. 59 Massoudi, M.S., Walsh, J., Stokley, S., et al. Assessing immunization performance of private practitioners in Maine: impact of the assessment, feedback, incentives, and exchange strategy. Pediatrics 103 (1999), 1218–1223.
60. 60 Fairbrother, G., Hanson, K.L., Friedman, S., Butts, G.C., The impact of physician bonuses, enhanced fees, and feedback on childhood immunization coverage rates. Am J Public Health 89 (1999), 171–175.